About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Pipeline Our promising pipeline of new mechanism antibiotics target a range of serious infectious diseases Home ∕ Our Programmes ∕ Pipeline Our Pipeline Discuva Platform Discovery Preclinical Phase 1 Phase 2 Phase 3 CDI (ridinilazole) Discovery Preclinical Phase 1 Phase 2 Phase 3 Enterobacteriaceae (DDS-04 Series) Discovery Preclinical Phase 1 Phase 2 Phase 3 ESKAPE programme
Pipeline Our promising pipeline of new mechanism antibiotics target a range of serious infectious diseases
Home ∕ Our Programmes ∕ Pipeline Our Pipeline Discuva Platform Discovery Preclinical Phase 1 Phase 2 Phase 3 CDI (ridinilazole) Discovery Preclinical Phase 1 Phase 2 Phase 3 Enterobacteriaceae (DDS-04 Series) Discovery Preclinical Phase 1 Phase 2 Phase 3 ESKAPE programme
